Sirtuin3 (SIRT3) is associated with oxidative stress and lifespan. However, the possible mechanisms underlying its influence are unknown. We hypothesized that SIRT3 increases the antioxidant capacity of aged cells and improves the efficacy of human mesenchymal stem cell (hMSC) therapy for ischaemic heart diseases in aged patients. In vitro, the antioxidant capacity of old hMSCs (O-hMSCs) was increased after SIRT3 overexpression using a gene transfection technique, while the antioxi- 
therapy for ischaemic heart diseases. [4] [5] [6] In early animal experiments, the treatment effect of young stem cell transplantation was satisfactory. 5 However, the therapeutic effect from old autologous stem cell transplantation was found to be limited in clinical trials. 7, 8 Our previous studies have revealed the close association between stem cell function and ageing. 9, 10 The regenerative capacity, biological activity and resistance to oxidative stress of stem cells significantly decline with age. This suggests that stem cell senescence is likely to be a major contributing factor to the ineffectual cell transplantation outcomes found in the clinical setting. We hypothesized that enhancing the function of old stem cells may improve the therapeutic effect of transplantation.
Sirtuin3 (SIRT3) is a deacetylase from the sirtuin family. 11, 12 There is significant evidence that SIRT3 localizes to mitochondria and plays a positive role in human longevity, organ ageing and stem cell function. [13] [14] [15] Human SIRT3 has two isoforms: a full-length isoform (fl-SIRT3) and a short one (sh-SIRT3) which is considered to have the most functional significance. [16] [17] [18] [19] Recent studies have reported that SIRT3 reduces levels of reactive oxygen species (ROS) by deacetylating the transcription factor forkhead box O3a (FoxO3a), which can then enter the nucleus and bind to the promoter of the genes encoding Mn-superoxide dismutase (MnSOD) and CAT. [20] [21] [22] Furthermore, many researchers have demonstrated that the elevated expression of MnSOD and CAT by SIRT3 overexpression can protect cells against the oxidative damage induced by ROS. 10, 17 In our previous study, we determined that the lower expression of sh-SIRT3 in old relative to young human myocardial tissue significantly contributed to myocardial ageing. 10 In addition, we showed that the decline in antioxidant capacity of old human MSCs (OhMSCs) is because of a substantially greater down-regulation of SIRT3 than that which occurs in young hMSCs (Y-hMSCs) under oxidative stress. 10 However, there is little evidence to support the potential association between SIRT3 and O-hMSC function. In this study, we explored the relationship and underlying mechanisms involved in SIRT3's influence on the antioxidant capacity of OhMSCs. We further investigated the efficacy of cell transplantation therapy when SIRT3-modified O-hMSCs were injected into the infarct region of the heart using a rat myocardial infarction (MI) model.
| MATERIALS AND METHODS

| Isolation and culture of hMSCs
Human bone marrow was acquired from the sternum of patients who underwent cardiac surgery at the Second Affiliated Hospital of Harbin Medical University. Informed consent was obtained for study participation, and the rights of infants and young children were entrusted to their parents. All protocols were reviewed and approved by the Research Ethics Board of the Harbin Medical University and conformed to the principles of the Declaration of Helsinki. O-hMSCs were obtained from patients 50-72 years of age (mean = 61.3 ± 9.5), and Y-hMSCs were obtained from patients 0-12 years of age (mean = 5.0 ± 4.9). MSCs were isolated by density gradient separation with Ficoll-Paque premium (1.073 g/mL density; GE Healthcare, Uppsala, Sweden) as described previously. 10 The 
| Plasmid and siRNA constructs
A plasmid containing a SIRT3 expression gene (pSIRT3) was constructed on a pEX-1 (pGCMV/MCS/EGFP/NEO) backbone (GenePharma, Shanghai, China). The plasmids were amplified and prepared using the Endofree maxi plasmid kit (TIANGEN, Beijing, China). The negative control (NC) and small interfering RNA (siRNA) were designed and synthesized by GenePharma to interfere with SIRT3 expression.
| Plasmid and siRNA transfection
The plasmid transfection was performed in accordance with the 
| Cell stress experiment
The transfection was performed as described above. (1:8000; ZSGB-BIO). Specific complexes were visualized on an X-ray film using electrochemi-luminescence (ECL) detection (Millipore) following the manufacturer's protocol. The levels of proteins were compared among groups by density and area using Quantity One software (Bio-Rad).
| Enzyme activity measurement of MnSOD and CAT
To measure enzyme activity, cultured cells were collected and protein extracted as outlined above. Enzyme activity was detected using the MnSOD Assay and CAT Assay kits (Beyotime) according to the manufacturer's protocol.
| Animal model and cell transplantation
All experiments were carried out according to the Guide for the Care 
CAT: catalase; MnSOD: Mn-superoxide dismutase; SIRT3: Sirtuin3.
group (O-hMSCs-pEX-1) and transplantation using O-hMSCs transfected with pSIRT3 group (O-hMSCs-pSIRT3).
| Infarct size measurement
Four weeks after MI and cell transplantation, rats were anaesthetized and respiration was assisted as described above. The heart was exposed through a median sternotomy, and 0.9% normal saline was continuously injected into the left ventricle of rats through the apex cordis using a syringe (20 mL). Meanwhile, the right atrium was carved to reduce the circulation load. Cardiac arrest in diastole was performed by injecting 10% KCL into the left ventricle when the myocardium blanched. Hearts were then excised, and an intraventricular balloon was inserted through the mitral valve and filled to 20 mm Hg pressure. Hearts were then fixed in formalin for 1 week under controlled pressure conditions and sliced. Sections were stained with Masson's trichrome to assess infarct size.
| Cardiac function assessment
Prior to and 1, 2 and 4 weeks after MI, rats were anaesthetized as 
| Cell apoptosis and survival evaluation in vivo
Three days after MI and cell transplantation, rats were sacrificed.
Briefly, rats were anaesthetized and respiration was assisted as above. The heart was exposed through a median sternotomy, the right atrium was carved to reduce the circulation load and 0.9% normal saline was continuously injected into the left ventricle through the apex cordis using a syringe (20 mL) until cardiac arrest occurred.
The hearts were excised as described above and sliced into 2-mm thick sections and fixed with 4% paraformaldehyde for 24 hours, followed by sucrose at varying concentrations and durations (10% for 1 hour, 20% for 1 hour and 30% for 24 hours). The tissues were then snap-frozen in moulds filled with optimal cutting temperature (OCT) compound (SAKURA, Torrance, CA, USA). The OCT-embedded tissues were cut into 5-μm-thick sections using a freezing microtome. 
| Statistical analysis
Data are expressed as mean ± standard deviation (SD). Analyses were conducted using GraphPad Prism 6.0 software (GraphPad, La Jolla, CA, USA). Comparisons between two groups were performed using two-tailed Student's t test. One-way ANOVA was used to determine the significance between three or more experimental groups. Repeated-measures ANOVA was used for left ventricular systolic function (ejection fraction and fractional shortening).
P < 0.05 was considered statistically significant.
| RESULTS
| Expression of SIRT3, MnSOD and CAT increase after transfection of SIRT3 in O-hMSCs
To study the effect of SIRT3 on the function of O-hMSCs, SIRT3
was transfected into O-hMSCs. Flow cytometry data showed that transfection efficiency was 14.1 ± 1.7% ( Figure 1A ,B, n = 6/group).
The gene and total protein expression of SIRT3 in the SIRT3 group was significantly higher compared to the Control group ( Figure 1C ,D, n = 6/group). Moreover, the protein expression of fl-SIRT3 and sh-SIRT3 both increased in the SIRT3 group compared with the Control group ( Figure 1E , n = 6/group). To further verify the activity of SIRT3 after transfection, gene and protein expression as well as activity of MnSOD and CAT were found to be increased after SIRT3 overexpression ( Figure 1F -K, n = 6/group). These results demonstrate that SIRT3 was successfully overexpressed in O-hMSCs using plasmid transfection, which correlated with antioxidant activity.
| Enhanced antioxidant capacity in O-hMSCs protects cells from oxidative stress injury
As shown in Figure 2 , the rate of apoptosis increased while the rate of cell survival decreased after oxidative stress induced by H 2 O 2 .
The apoptosis rate was significantly lower and the survival rate significantly higher in the SIRT3+ group than the Control+ group, while there were no significant differences between the SIRT3 and Control groups, which were free from oxidative stress (n = 6/group). We fur- | 5507
and SIRT3+ groups than in the non-H 2 O 2 -treated groups (Control and SIRT3). However, these levels were still significantly higher in the SIRT3+ group than the Control+ group ( Figure 3A-C) . The mRNA, protein and enzyme activity levels of MnSOD and CAT which decreased after oxidative stress were still significantly higher in the SIRT3+ group than the Control+ group ( Figure 3D-I ).
F I G U R E 1 Transfection of sirtuin3 (SIRT3) enhanced expression of SIRT3, Mn-superoxide dismutase (MnSOD) and catalase (CAT) in old human mesenchymal stem cells (hMSCs). A,B, Transfection efficiency of O-hMSCs (14.1 ± 1.7%) was detected by fluorescence activated cell sorting (FACS). Scale bars represent 50 μm. C,D, Gene and total protein expression of SIRT3 was significantly higher in the SIRT3 group than the Control group. E, Protein expression level of fl-SIRT3 and sh-SIRT3 was significantly greater in the SIRT3 group compared with the Control group. F,G,I,J, Gene and protein expression of MnSOD and CAT was significantly greater in the SIRT3 group compared with the Control group. H,K, Enzyme activity of MnSOD and CAT was significantly greater in the SIRT3 group compared with the Control group (two-tailed t test; *P < 0.05; **P < 0.01; n = 6/group) After pSIRT3 transfection, FoxO3a protein expression significantly increased in the nuclear fraction ( Figure 3J ). After H 2 O 2 treatment, the expression of FoxO3a protein in the nucleus was significantly lower in the Control+ and SIRT3+ groups than the Control and SIRT3 groups. However, the level was still significantly higher in the SIRT3+ group than the Control+ group ( Figure 3J ).
These findings suggest that the antioxidant capacity of O-hMSCs was enhanced by SIRT3 overexpression, likely by increasing expression and activity of MnSOD and CAT via transferring FoxO3a into the nucleus.
| Silencing SIRT3 reduces antioxidant capacity of Y-hMSCs
The expression of SIRT3 was reduced using silencing RNA transfection in Y-hMSCs. The rate of apoptosis increased while the cell survival rate decreased after cells were exposed to H 2 O 2 treatment.
Cellular apoptosis was significantly higher and cell survival significantly lower in the siSIRT3+ group than the Control+ group, and there were no differences between the Control and siSIRT3 groups 
| Cardiac function is enhanced following transplantation of SIRT3-overexpressed O-hMSCs
Echocardiography was conducted before and 1, 2 and 4 weeks after
MI. Ejection fraction (EF) and fractional shortening (FS) significantly
increased in the O-hMSCs-pSIRT3 group compared to the medium control and O-hMSCs-pEX-1 groups, and there were no significant differences between the medium control and O-hMSCs-pEX-1 groups ( Figure 6C -E, n = 6/group). The LVEDV and LVESV of the OhMSCs-pSIRT3 group after MI were significantly smaller than that of the medium control and O-hMSCs-pEX-1 groups, and there were no significant differences between the medium control and O-hMSCspEX-1 groups ( Figure 6F ,G, n = 6/group). These results suggest that transplantation of SIRT3-modified O-hMSC improves cardiac function after MI.
| SIRT3 overexpression decreases number of apoptotic cells and increases number of remaining transplanted cells
To further investigate the effect of SIRT3 on the function of OhMSCs, SIRT3-modified O-hMSCs were transplanted into the local hypoxic-ischaemic region after MI in vivo. The number of apoptotic cells (TUNEL+) in the border region was significantly less in the OhMSCs-pSIRT3 group than O-hMSCs-pEX-1 group 3 days after cell transplantation ( Figure 7A -B, n = 6/group). To investigate the survival of O-hMSCs in the local hypoxic-ischaemic region, immunofluorescence staining of human-specific mitochondria was used. The F I G U R E 4 Sirtuin3 (SIRT3) silencing weakened the antioxidant capacity of young human mesenchymal stem cells (hMSCs) against oxidative stress. A, Terminal dUTP nick-end labelling (TUNEL) staining of apoptotic cells (arrows) in the four groups. Scale bars represent 50 μm. B, The rate of cell apoptosis was significantly higher in the siSIRT3+ than the Control+ group while there was no significant difference between the siSIRT3 and Control groups. C, The cell survival rate in the siSIRT3+ group was significantly lower than the Control+ group, and there was no significant difference between the siSIRT3 and Control groups. (ANOVA; **P < 0.01; n = 6/group) number of O-hMSCs in the infarct border zone was significantly greater in the O-hMSCs-pSIRT3 group than the O-hMSCs-pEX-1 group 3, 7 and 28 days after cell transplantation ( Figure 7C -D, n = 6/ group). These results suggest that the apoptosis and survival of OhMSCs was optimized by SIRT3 overexpression.
| DISCUSSION
The efficacy of current therapies for ischaemic heart diseases in aged patients is limited. 2, 3 In previous pre-clinical studies, young MSC transplantation has been demonstrated as an effective therapy for ischaemic heart diseases. 5 The use of hMSCs is safe and feasible in the clinical setting, and these cells have been used in multiple clinical trials. 8 However, most studies used autologous O-hMSCs because most patients with ischaemic heart diseases are older. 7, 23 The efficacy of these aged cells was found to be unsatisfactory potentially because of their decreased function. 9 Improving the function of O-hMSCs may improve the therapeutic effect of autologous stem cell transplantation in older patients.
Sirtuin3 (SIRT3) is a class III deacetylase depending on the nicotinamide adenine dinucleotide (NAD+) and belongs to the highly conserved Sirtuin family. 11, 12, 19 As a mitochondria-localized protein, SIRT3
mainly exists in tissues and organs that are rich in mitochondria such as the kidney, brain, heart and liver. 18 Human SIRT3 has two isoforms: fl-SIRT3 and sh-SIRT3. [16] [17] [18] [19] Previous studies, including our own, have
shown that the short isoform of SIRT3 has the most functional significance. [16] [17] [18] [19] In the current study, the expression level of sh-SIRT3 was down-regulated by oxidative stress which is consistent with previous research. [16] [17] [18] SIRT3 has been shown to be protective against oxidative stress, but the majority of these studies were performed on animals, cell lines and tumour cells. It has been demonstrated that the expression of MnSOD and CAT can be up-regulated by SIRT3 overexpression. 10, 17 In agreement with previous studies, the expression levels of MnSOD and CAT were found to be positively associated with SIRT3 expression in the current study. The expression levels of SIRT3, MnSOD and CAT were down-regulated by H 2 O 2 treatment, revealing that SIRT3,
MnSOD and CAT were involved in oxidative stress. The expression levels of SIRT3, MnSOD and CAT were higher in the SIRT3 group than the empty vector group, and these expression levels were decreased in the siRNA-transfected group compared with the control group after H 2 O 2 stress. This suggests that SIRT3 overexpression improved the antioxidant capacity of hMSCs by increasing the expression of MnSOD and CAT. The deacetylation of protein is a common phenomenon in mitochondria. 27 As a deacetylase, the main function of SIRT3 is to deacetylate the transcription factor FoxO3a which can enter the nucleus and activate expression of MnSOD and CAT to reduce ROS content. [20] [21] [22] 28 In this study, the expression level of FoxO3a in nuclear fraction was also positively associated with the expression of SIRT3, MnSOD and CAT. These results suggest that SIRT3 overexpression enhanced antioxidant capacity via the FoxO3a-MnSOD and CAT pathway in O-hMSCs, similar to that which occurs in other classes of cells. There are some limitations to this research. As previously reported, SIRT3 regulates activation of oxidative metabolism and mitochondrial fatty-acid oxidation through deacetylation of numerous mitochondrial enzymes. 29, 30 In the current study, we did not investigate mitochondrial function because we focused on cellular function. Future work will investigate the comprehensive function of SIRT3.
Studies have verified that the benefit of stem cell transplantation is dependent upon the number of residual transplanted cells in the local hypoxic-ischaemic environment after MI. 31, 32 We have confirmed that the ability of O-hMSCs to resist oxidative stress in vitro was improved by SIRT3 overexpression. We further proposed that the number of remaining stem cells would be increased after OhMSC transplantation and that the therapeutic effect of cell transplantation would be improved by SIRT3 overexpression in vivo.
In the in vivo experiment, the number of apoptotic cells was found to be less in the O-hMSCs-pSIRT3 group than the O-hMSCspEX-1 group after short-term acute ischaemia and hypoxia (3 days after MI). Furthermore, O-hMSC survival decreased with time after MI. However, more O-hMSCs survived after pSIRT3 transfection than pEX-1 transfection in acute and chronic ischaemia and hypoxia.
These results suggest that SIRT3 protects O-hMSCs against anoxia and ischaemic injury in vivo and the protective effect is persistent.
Although we found that ejection fraction and fractional shortening significantly declined after MI, the reduction in cardiac function was relatively less in the O-hMSCs-pSIRT3 group than the O-hMSCspEX-1 group 7 days after MI. Twenty-eight days after MI, cardiac function remained at a higher level in the O-hMSCs-pSIRT3 group than the control group. LVEDV and LVESV significantly increased after MI. However, the increment in volume was relatively smaller in the O-hMSCs-pSIRT3 group than the control groups, especially for LVESV. We further discovered that infarct size was the smallest in 
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